catalyst
as of 2026-07-01A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schi — primary completion
at a glance
2024-08-15 · Actual — This event happened.
Synthesized from structured facts only — each point cited above.
Event
What
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schi — primary completion
Type
Trial Readout
Date
2024-08-15
Date type
ACTUAL
Phase
Phase 2
This event happened.
relationships
The graph out of here